FDA opens door to new response criteria for cancer immunotherapies

FDA wants to see companies test new immune-specific response endpoints in clinical trials, but first the companies should work with the agency to ensure that bias is minimized and the studies are well controlled.

The comments came at a Thursday workshop co-hosted by FDA and the Society for Immunotherapy of Cancer (SITC) as

Read the full 527 word article

User Sign In